Section Arrow
CGON.NASDAQ
- CG Oncology
Quotes are at least 15-min delayed:2026/07/10 03:56 EDT
Pre Market
Last
 --
-- (--)
Bid
--
Ask
--
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 73.32
+3.52 (+5.04%)
Day High 
73.88 
Prev. Close
69.8 
1-M High
77 
Volume 
776.90K 
Bid
--
Ask
--
Day Low
70.12 
Open
70.12 
1-M Low
54.1 
Market Cap 
6.16B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 70.78 
20-SMA 65.5 
50-SMA 64.65 
52-W High 77 
52-W Low 23.65 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.34/-2.75
Enterprise Value
6.16B
Balance Sheet
Book Value Per Share
12.38
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
191.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
VRAXVirax Biolabs Group Limited6.36+3.18+100.00%-- 
Pre Market -- -- --
EVGNEvogene Ltd.0.5+0.0859+20.74%-- 
Pre Market -- -- --
RXRXRecursion Pharmaceuticals3.76+0.04+1.08%-- 
Pre Market -- -- --
IONSIonis Pharmaceuticals64.27-20.19-23.90%-- 
Pre Market -- -- --
BBIOBridgeBio Pharma90.17+11.84+15.12%-- 
Pre Market -- -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.